NASDAQ
AbbVie Inc. (ABBV) has a consensus Buy rating from 41 analysts with an average price target of $256.92, representing +15.5% upside from the current price of $222.47.
| Date | Analyst | Firm | Target | Price | Upside |
|---|---|---|---|---|---|
| May 15, 2026 | Unknown | Evercore ISI | $235.00 | $212.04 | +10.83% |
| May 14, 2026 | Unknown | Piper Sandler | $298.00 | $208.50 | +42.93% |
| Apr 30, 2026 | Unknown | Morgan Stanley | $278.00 | $212.15 | +31.04% |
| Apr 23, 2026 | Unknown | Piper Sandler | $294.00 | $200.49 |
May 15, 2026 | Maintained | Evercore ISI Group | Outperform | Outperform |
May 14, 2026 | Maintained | Piper Sandler | Overweight | Overweight |
May 4, 2026 | Maintained | Evercore ISI Group | Outperform | Outperform |
May 1, 2026 | Maintained | Guggenheim | Buy | Buy |
Apr 30, 2026 | Maintained | Cantor Fitzgerald | Overweight | Overweight |
| +46.64% |
| Apr 20, 2026 | Unknown | Canaccord Genuity | $262.00 | $203.71 | +28.61% |
No price data available for this timeframe.